Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...
Zacks.com on MSN4d
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...
Recent 5.4% pullback isn't enough to hurt long-term Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders, they're still up 159% over 3 years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
bovnews2d
Vertex Pharmaceuticals Incorporated (VRTX) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...
Impacts4d
The Role of Vertex Pharmaceuticals in Boston’s Biotech Boom
Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with groundbreaking discoveries, cutting-edge research, and influential biotech ...
Eagle-Tribune1d
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and ...
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.
Business Wire8d
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...
BioSpace2d
Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs
Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...